Soluble Guanylyl Cyclase

A mammalian enzyme composed of a heterodimer of alpha and beta subunits. Each subunit consists of four domains; N-terminal HNOX domain, PAS-like domain, a coiled-coil domain, and a C-terminal catalytic domain. All four domains are homologous proteins with a similar conformation of functional domains. Soluble guanylate cyclase catalyzes the formation of cyclic GMP from GTP, and is a key enzyme of the nitric oxide signaling pathway involved in the regulation of a variety of biological and physiological processes in mammals.

Also Known As:

Networked: 780 relevant articles (58 outcomes, 94 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stasch, Johannes-Peter: 41 articles (12/2021 - 02/2003)
2.	Buys, Emmanuel S: 19 articles (01/2022 - 01/2009)
3.	Brouckaert, Peter: 19 articles (10/2017 - 08/2006)
4.	Frey, Reiner: 16 articles (04/2019 - 12/2008)
5.	Grimminger, Friedrich: 16 articles (05/2017 - 01/2006)
6.	Sandner, Peter: 15 articles (07/2022 - 11/2011)
7.	Hoeper, Marius M: 14 articles (01/2021 - 03/2009)
8.	Becker, Corina: 13 articles (11/2022 - 03/2016)
9.	Ghofrani, Hossein-Ardeschir: 13 articles (01/2021 - 07/2013)
10.	Roessig, Lothar: 12 articles (11/2021 - 03/2013)

Related Diseases

1.	Pulmonary Hypertension 10/01/2022 - "Should we Consider the Stimulation of Soluble Guanylyl Cyclase as Beneficial for Treating Pre-Capillary Pulmonary Hypertension?" 01/01/2022 - "Modulation of soluble guanylate cyclase ameliorates pulmonary hypertension in a rat model of chronic thromboembolic pulmonary hypertension by stimulating angiogenesis." 01/01/2016 - "The first large randomized controlled trial showing a positive treatment effect was the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial (CHEST). " 01/01/2016 - "There is no substitute for experience: Lessons learned from CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) for future clinical trial design." 01/01/2016 - "We discuss the implications for future clinical trials and practice of a unique operability assessment in patients who have chronic thromboembolic pulmonary hypertension and were initially screened for inclusion in the CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) study. "
2.	Heart Failure 09/01/2021 - "We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. " 11/22/2023 - "We conducted a systemic review and meta-analysis to evaluate the therapeutic efficacy and safety of soluble guanylate cyclase(sGC) stimulators in patients with heart failure with preserved ejection fraction(HFpEF). " 10/26/2020 - "Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis." 11/01/2021 - "Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials." 10/01/2018 - "Several randomized controlled trials (RCTs) have been investigated the benefits of soluble guanylate cyclase (sGC) stimulators in the treatment of heart failure, but a comprehensive evaluation is lacking. "
3.	Pulmonary Arterial Hypertension 06/01/2012 - "Stimulators of soluble guanylate cyclase (sGC) are vasoactive drugs that are currently being evaluated in phase III clinical trials for pulmonary arterial hypertension. " 01/01/2023 - "Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)." 04/15/2021 - "The soluble guanylate cyclase (sGC)/GMPc pathway plays an important role in controlling pulmonary arterial hypertension (PAH). " 12/01/2011 - "Recently, direct activators of soluble guanylyl cyclase (sGC) have been tested as a novel therapeutic modality in experimental models of pulmonary arterial hypertension (PAH). " 10/01/2008 - "Soluble guanylate cyclase may thus offer a new target for therapeutic intervention in pulmonary arterial hypertension."
4.	Hypoxia (Hypoxemia) 10/01/2009 - "The aim of this study was to explore the interaction between HIF-1alpha and soluble guanylate cyclase (sGC) and its second messenger cGMP in cultured cardiomyocytes exposed to hypoxia and in pressure-overloaded heart. " 07/01/2009 - "The present study explores the general hypothesis that chronic hypoxia also modulates cerebrovascular reactivity to NO, and does so by modulating the activity of soluble guanylate cyclase (sGC), the primary target for NO in vascular smooth muscle. " 10/01/1999 - "In this study, we examined the expression and localization of soluble guanylate cyclase (sGC), the primary receptor for NO, in hypoxia- and normoxia-treated rat lungs. " 12/20/2021 - "Since 1994, YC-1 (Lificiguat, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole) has been synthesized, and many targets for special bioactivities have been explored, such as stimulation of platelet-soluble guanylate cyclase, indirect elevation of platelet cGMP levels, and inhibition of hypoxia-inducible factor-1 (HIF-1) and NF-κB. " 08/01/2020 - "The exact interactions between hypoxia, anaerobic metabolism and NQO-1 leading to biased activity of soluble guanylyl cyclase remain to be established."
5.	Reperfusion Injury 01/01/2013 - "We hypothesized that delivery of CO via a novel releasing molecule (CORM) would impart neuroprotection in vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells (RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase (sGC). " 12/01/2022 - "Targeting soluble guanylate cyclase with Riociguat has potency to alleviate testicular ischaemia reperfusion injury via regulating various cellular pathways." 10/01/2021 - "We assessed the hypothesis that the soluble guanylate cyclase activator cinaciguat would protect the vascular graft against ischaemia-reperfusion injury. " 05/15/2012 - "The hepatic soluble guanylyl cyclase-cyclic guanosine monophosphate pathway mediates the protection of remote ischemic preconditioning on the microcirculation in liver ischemia-reperfusion injury." 10/01/2007 - "However, these pathologic actions of (ONOO-) may have been overemphasized, in that (ONOO-) has vasorelaxant properties through activation of soluble guanylate cyclase; inhibits leukocyte-endothelial cell interactions; and reduces ischemia-reperfusion injury in the heart, lung, and liver. "

Related Drugs and Biologics

1.	riociguat
2.	vericiguat
3.	Nitric Oxide (Nitrogen Monoxide)
4.	Guanosine Monophosphate (5' Guanylic Acid)
5.	Methylene Blue (Methylthioninium Chloride)
6.	Nitric Oxide Synthase (NO Synthase)
7.	Type 5 Cyclic Nucleotide Phosphodiesterases
8.	Endothelin Receptor Antagonists
9.	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)
10.	Phosphodiesterase 5 Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Endarterectomy (Thromboendarterectomy)
3.	Ligation
4.	Ischemic Postconditioning
5.	Cardiopulmonary Resuscitation (CPR)